Table 2.
Area under the change from baseline curve from 0 to 2 hours for throat soreness (measured on an 11-point scale where 0 = not sore and 10 = very sore)
| Flurbiprofen 8.75 mg | Placebo | |
|---|---|---|
| Intent-to-treat population | ||
| n | 186 | 187 |
| Mean ± SD | –2.14 ± 1.735 | –1.65 ± 1.668 |
| Least squares meana | –2.29 | –1.81 |
| Difference between least squares meansb | –0.48 | |
| 95% CI | –0.81 to –0.15 | |
| P-value for treatmenta | 0.0049 | |
| Per protocol population | ||
| n | 173 | 173 |
| Mean ± SD | –2.14 ± 1.770 | –1.67 ± 1.670 |
| Least squares meana | –2.29 | –1.83 |
| Difference between least squares meansb | –0.46 | |
| 95% CI | –0.81 to –0.11 | |
| P-value for treatmenta | 0.0097 |
a
Estimated from analysis of covariance model with factors for treatment and centre and a covariate for baseline throat soreness severity.
b
Flurbiprofen 8.75mg microgranules minus placebo. A negative difference favours flurbiprofen 8.75mg microgranules. SD = standard deviation.